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In normal colon epithelium there is constitutive low level
expression of COX-1, but not COX-2, whereas tumors
have high level expression of COX-2 (Eberhart et al.,
Colon cancer is a paradigm for the multistep genetic
1994; Sano et al., 1995; Kutchera et al., 1996). The work
basis of cancer. Several initiating mutations have been reported by Oshima et al. (1996) clearly demonstrates
identified by studying families with inherited predisposi- that COX-2 lies on the standard route from mutations
tion to colon cancer and its long-lived intermediate, the in APC to colon tumors.
adenomatous polyp. For example, in Familial Adenoma-
In the APC1/2 mouse created by Oshima et al. (1995)
tous Polyposis the affected individuals develop hun- and in the Min mouse, early adenomas have lost both
dreds of polyps, some of which progress to cancer. copies of APC and overexpress COX-2 (Oshima et al.,
The FAP gene was mapped to chromosome 5q21 and 1996; Dove et al., 1995). Are the two causally related?
mutations in the APC gene were identified as the cause That is, does the rise in COX-2 require that there be
(reviewed by Kinzler and Vogelstein, 1996). Insight into loss of function at both alleles of APC, or could COX-2
how these mutations result in cancer has been acceler- expression occur when the cells are still heterozygous?
ated by the discovery of the Min mouse, which has a The upstream boundary for COX-2 expression (see Fig-
mutated APC gene and a similar syndrome (reviewed ure 1) was set in experiments that examined adenomas
by Dove et al., 1995). Studies of the biochemical mecha- and normal tissue from APC1/2 mice. Two groups found
nisms downstream of APC mutations have turned up that there was no COX-2 in the uninvolved colon, but
important leads (Kinzler and Vogelstein, 1996); the over- that it was present in the tumor (Williams et al., 1996;
expression of prostaglandin H synthase-2 (COX-2) is Oshima et al., 1996). Earlier, Oshima et al. (1995) showed
one of the most significant since it has immediate impli- that even small adenomas showed loss of heterozygos-
cations for prevention of colon cancer. ity at the normal APC allele. Taken together, these find-
A paper in this issue of Cell (Oshima et al., 1996) ings tentatively place the time of COX-2 induction after
provides key evidence on the role of COX-2 in colon the loss of the second APC allele. In support of this,
carcinogenesis. They bred mice carrying an APC muta- Oshima et al. (1996) did not detect COX-2 protein in
tion with a mouse with a disrupted COX-2 gene. All of polyps smaller than 2 mm, which would indicate that
the animals were APC1/2; if homozygous for wild type the tumor has been initiated before COX-2 is expressed.
COX-2, they developed an average of 652 polyps at 10 However, Boolbol et al. (1996) obtained a directly con-
weeks, while heterozygotes had 224 polyps and homo- flicting result—that the uninvolved epithelium in Min
zygously deficient mice had only 93 polyps. This experi- mice did have increased COX-2, which will need to be
ment provided definitive genetic evidence that induction assessed further in mice and humans. We conclude that
of COX-2 is an early, rate-limiting step for adenoma the current evidence supports this sequence of events:
formation. As supporting evidence, a drug that inhibits loss of both APC alleles, early polyp formation, expres-
COX-2 but not COX-1 also markedly reduced the num- sion of COX-2, polyp growth, and additional mutations
ber of polyps. Thus, a mouse model again has proven to reach an invasive tumor (Figure 1). Thus, COX-2 ex-
valuable for measuring a quantitative genetic effect and pression would be past the boundary of tumor establish-
Ptgs2 (the COX-2 gene in mouse terminology) can be ment (Dove et al., 1995) and would provide a mechanism
added to the list of genes involved in colon neoplasia for self-promotion by the early adenoma.
(Dove et al., 1995). The events between loss of the second APC allele and
Overexpression of COX-2 Is an Early, Central Event COX-2 expression are unknown. One likely possibility is
in Carcinogenesis that transcription of COX-2, which does not occur con-
A connection between prostaglandins and colon carci- stitutively, is switched on. We found that a colon cancer
nogenesis has been recognized for some time; epide- cell line that expresses COX-2 also transcribes a COX-2
miological studies have shown that chronic intake of reporter gene, which is consistent with this hypothesis
nonsteroidal anti-inflammatory drugs (NSAIDs), which (Kutchera et al., 1996). There is substantial information
function as COX inhibitors, reduce colon cancer and about the transcriptional regulation of COX-2 (Hersch-
polyps by as much as 40%. NSAIDs prolong the lag man, 1994), but it is not clear how loss of APC function
phase prior to the appearance of colon cancer induced would activate these pathways. Another mechanism is
by chemical carcinogens in animals and decrease the suggested by recent studies of APC function: APC binds
number of polyps in Min mice (Jacoby et al., 1996). to b-catenin and it, in turn, binds and regulates the
Finally, the size and number of polyps in FAP patients transcription factor LEF-1 (Kinzler and Vogelstein, 1996).
decrease markedly in response to the NSAID sulindac LEF-1 is not known to regulate COX-2 expression, but
(Giardiello et al., 1993). There was substantial circum- such a mechanism could link APC loss with increased
COX-2 transcription.stantial evidence that COX-2 was the culprit; COX-1
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Figure 1. Prostaglandin Synthase-2 (COX-2) Is an Early, Causal Event in the APC Pathway to Colon Polyps and Cancer
Recent evidence (including Oshima et al., 1996) places COX-2 after the loss of the second allele of APC and the morphological appearance
of a very early polyp (<2 mm). Mice that are genetically altered to be COX-2 deficient, or that receive a selective inhibitor of COX-2, are
strongly protected against the development of colon polyps even with a germline mutation in APC. The steps between functional loss of both
APC alleles and increased expression of COX-2 are unknown but likely involve increased transcription of this normally silent gene. Once
expressed, the majority of COX-2 is strategically located in the nuclear membrane (DeWitt and Smith, 1995). The mechanism(s) by which
increased prostaglandin synthesis promote tumorigenesis also is unknown but there are several promising clues. One intriguing finding is
that expression of COX-2 impairs the apoptotic response (Tsujii and DuBois, 1995).
In a recent minireview, DeWitt and Smith (1995) asked but remained far higher than mice that were APC1/1.
Thus, there clearly is a way around COX-2: is it COX-1,whether increased COX-2 has a causal role in colon
or another oxidase? It would be interesting to testcarcinogenesis. This question now is resolved: COX-2
whether a COX-1 inhibitor reduces the neoplasia inis on the causal pathway. In its absence—whether by
COX-2 deficient/APC1/- mice relative to that of controlpharmacological inhibition or genetic alteration—ade-
animals.noma formation is substantially impaired. A related
How Do COX-2 Reaction Products Contributequestion posed then was, if COX-2 has a causal role
to Tumorigenesis?why isn’t its expression consistently observed in human
Prostaglandins are a diverse family of lipid mediatorspolyps at an early stage? The answers to the seeming
derived from arachidonic acid. The committed step inparadox are arriving. In part, the previous results could
their synthesis is prostaglandin H synthase (COX), whichhave reflected simply a lack of sufficient sensitivity in
catalyzes two reactions (Figure 2). The cyclooxygenasethe methods applied. Also, recent reports have lessened
reaction incorporates two moles of oxygen per mole ofthe paradox: both Oshima et al. (1996) and Williams et
arachidonic acid to yield PGG2. This intermediate isal. (1996) found that the adenomas from APC1/1 mice
reduced by the peroxidase activity of COX to PGH2have increased expression of COX-2. Finally, many of
which, in turn, can be converted by other enzymes intothe adenomas negative for COX-2 were sporadic, and
one of many terminal prostaglandins. Alternatively,sporadic adenomas may follow a different pathway. Be-
PGH2 can break down to a direct mutagen, malondialde-
cause mutation or deletion of APC is frequently ob-
hyde, which forms adducts with deoxynucleosides. The
served in sporadic polyps, it seems unlikely that the
peroxidase reaction could be important in carcinogene-
sporadic pathway is completely different, but the ques-
sis since it requires a cofactor as the reductant; many
tion still remains as to whether the sporadic pathway
depends as heavily on COX-2. Also, another inherited
syndrome, Hereditary Nonpolyposis Colorectal Cancer
(which does have polyps in spite of the name), is initiated
through mutation of DNA mismatch repair genes. Does
this pathway involve COX-2? The colon cancer cell line
HCT116 has constitutive expression of COX-2 (Kutchera
et al., 1996), but has a mutation in a mismatch repair
gene and expresses normal APC alleles. Is this a coinci-
dence resulting from a later mutation or does it indicate
that COX-2 is an early event in both pathways?
The demonstration of an important role for COX-2 in
colon neoplasia raises the question of whether it is ab-
solutely essential. The answer seems to be no, even
though it appears to be the standard early step on the
APC pathway. The best evidence against an absolute
role comes again from the results from Oshima et al.
Figure 2. Reactions Catalyzed by Prostaglandin Synthase(1996): in their mice homozygously deficient for the
COX-2 gene, the number of polyps was reduced by 86% See text for details.
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immunohistochemistry even though it was evident by
western blotting. To address this, they constructed a
mouse with b-galactosidase under the control of the
COX-2 promoter. Their surprising result was that expres-
sion was observed in interstitial, rather than epithelial,
cells. If this reflectsexpression of theendogenousCOX-2
gene, the implications would be profound—the role of
COX-2 products presumably would be through para-
crine signaling and not by a cell-autonomous mecha-
nism. This would raise many more questions, including
whether the interstitial cells are responding to a signal
from epithelial cells to induce COX-2. However, this
result needs more investigation since it is at odds with
other findings in the Min mouse (Williams et al., 1996) and
human tissues (Sano et al., 1995; Kutchera et al., 1996),
in whichneoplastic epithelial cells had markedly increased
COX-2 expression.
Future Prospects
Oshima et al. (1996) have proven that COX-2 expression
Figure 3. Mechanisms by Which Prostaglandins Regulate Cellular is an early event in the APC pathway of colon neoplasia,
Events which suggests that drugs that inhibit COX-2 should be
See text for details. broadly effective in chemoprevention of colon cancer.
Much remains to be learned: in the clinic, will specific
inhibitors of COX-2 be more effective than those that
compounds (for example, xenobiotics such as aflatoxin) inhibit both isoforms? Will inhibition of COX-2 be as
can be oxidized by COX to mutagens (Marnett, 1994, effective in sporadic polyps and HNPCC as in FAP pa-
and references therein). This might be a particularly im- tients? What accounts for the residual cases of neopla-
portant mechanism in the colon since the epithelial cells sia—is it a rare event that occurs only in some early
are continuously exposed to xenobiotics. polyps, or will all of them eventually escape the inhibitory
It seems most likely that the products of COX-2 cause effect? How should chemoprevention with COX inhibi-
tumor promotion, but prostaglandins also are known to tors be integrated into current surveillance and interven-
alter cell growth. This probably occurs throughparacrine tion protocols? In the laboratory, there also are impor-
or autocrine signaling through prostaglandin receptors, tant questions: how does COX-2 expression become
which are members of the G protein-coupled family of dysregulated after loss of APC function? Is it transcrip-
receptors (Figure 3). The signals depend on the specific tional, and, if so, through which factors? Is COX-2 ex-
agonist and receptor, but include changes in cyclic pression alone sufficient to cause colon neoplasia?
AMP, turnover of phosphatidylinositol, and activation of What are the important products and what is the signal-
both PKC and MAP kinase. Another possibility is that ing pathway? Which cellular responses lead to tumors
COX-2 regulates apoptosis in colonic epithelial cells. In (e.g., loss of apoptosis, others)? The distance ahead
normal colon, the epithelial cells arise from stem cells, shouldn’t obscure how successful the journey has been
differentiate, and then undergo apoptosis, which several already: an early, central biochemical step incolon carci-
groups have shown to be decreased in tumorigenesis nogenesis has been identified by pharmacological and
(reviewed by Kinzler and Vogelstein, 1996). An important genetic approaches. Also, there are safe inhibitors of the
insight into this process came from Tsujii and DuBois enzyme, suggesting that application to clinical practice
(1995), who showed that overexpression of COX-2 in should follow promptly.
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